# LMA-Aligned Positioning Memo: Neuravant as AI Assurance & Underwriting Evidence Infrastructure

## Executive Position

The Lloyd’s market is no longer asking whether AI will be used in insurance. It is asking how AI can be adopted with governance, accountability, oversight, validation, and usable evidence.

The LMA’s recent AI material is therefore a commercial signal for Neuravant: the opportunity is not to sell “AI automation” into insurers, but to provide the assurance layer that lets insurers, brokers, underwriters, chief actuaries, chief risk officers, and claims teams trust AI-enabled workflows.

Neuravant should position itself as **AI Assurance & Underwriting Evidence Infrastructure** for agentic and AI-assisted insurance operations.

## Source Signals From LMA Material

The LMA page **“AI Governance in the Lloyd’s Market”** states that its latest survey focused on the maturity and breadth of AI frameworks in the Lloyd’s market, with particular attention on governance processes for managing AI adoption risk.

Key market signals from the LMA page:

- The report was based on **39 survey responses**, representing **over 60% of market stamp capacity**, plus **11 in-depth interviews**.
- The LMA states that **93% of respondents** have an AI governance framework either already in place or in development.
- AI adoption has accelerated: at the start of 2025 only **25%** of respondents reported using AI, while one year later the majority were actively adopting these technologies.
- The market is still at an early stage, with scope for more advanced applications.
- The LMA has published an **AI Adoption Toolkit** to help managing agents implement AI in a structured and responsible way.
- The earlier LMA report, **“Artificial intelligence and machine learning in actuarial and risk”**, identified regulatory oversight and absence of robust governance frameworks as key barriers to adoption.

The practical message is clear: governance is moving from a theoretical compliance concern to a procurement and operating requirement.

## Why This Matters Commercially

The market has crossed from curiosity into controlled adoption. That creates demand for systems that can evidence whether AI behaved within policy, whether human oversight was preserved, whether controls worked, and whether exceptions were handled safely.

This is stronger than a generic “AI analytics” opportunity. Analytics answers: “What does the model predict?” Neuravant should answer: “Can this AI-enabled process be trusted, governed, underwritten, audited, and defended after an incident?”

That distinction matters because insurers do not only need better models. They need defensible AI operating records.

## Where Neuravant Fits

Neuravant should avoid being framed as a black-box model vendor. The better position is an assurance layer around models, agents, tools, workflows, and human decisions.

| LMA / Lloyd’s Market Need | Neuravant Fit |
| --- | --- |
| AI governance frameworks | Policy-to-control mapping, runtime controls, audit-ready evidence |
| Human oversight | Human approval, override, attribution, and escalation records |
| Risk management | AI risk tiering, anomaly detection, containment decisions |
| Validation and monitoring | Runtime telemetry, drift/anomaly indicators, control effectiveness metrics |
| Accountability | Signed, hash-linked evidence chain for decisions and incidents |
| Vendor and third-party risk | Tool-use logs, system boundaries, external-call evidence, data-access records |
| Claims defensibility | Timeline of AI action, human action, control response, and evidence integrity |

The strategic claim should be:

> Neuravant gives insurers the evidence layer required to adopt AI safely, govern it continuously, and defend decisions when underwriting, compliance, or claims questions arise.

## Product Implications

The LMA material implies four near-term product requirements.

### 1. Governance Mapping

Every Runtime Sensor or NAIL Enforce output should map observed behaviour to governance controls:

- AI use case and business owner
- Risk tier
- Human oversight point
- Policy or control breached
- Evidence generated
- Escalation or containment action

This turns runtime monitoring into an underwriter-readable governance artefact.

### 2. Human Accountability

The product should distinguish between:

- Autonomous agent action
- Human-approved action
- Human override
- Human error
- Tool or vendor failure
- Control failure

This is critical for insurance because causation and attribution determine claims handling, exclusions, remediation, and future pricing.

### 3. Runtime Evidence

Static model documentation is not enough for agentic systems. Neuravant should emphasise live operational evidence:

- Tool calls
- Process creation
- Sensitive file access
- Network behaviour
- Retry loops
- Privilege probes
- Policy decisions
- Containment response
- Evidence hashes

This is where the Runtime Sensor becomes strategically important. It provides proof of what happened, not just an explanation of what a model was intended to do.

### 4. Underwriter Evidence Pack

The product should package outputs in a form an insurer can use:

- Executive summary
- Scenario risk score
- Risk tier
- Control effectiveness
- Human oversight status
- Evidence chain verification
- Incident timeline
- Recommended exclusions, warranties, or controls

This should become a repeatable evidence pack for pilot discussions with Hiscox, Lloyd’s participants, brokers, and managing agents.

## Hiscox / Underwriter Framing

For Hiscox or similar underwriting conversations, the strongest framing is:

> AI adoption is accelerating in the Lloyd’s market, but firms still need defensible governance and operational evidence. Neuravant provides runtime assurance for AI agents: who acted, what tool was used, what policy applied, whether a human approved it, what containment happened, and whether the evidence chain remained intact.

Avoid leading with:

- “We stop rogue AI.”
- “We solve AI safety.”
- “We replace actuarial judgement.”
- “We provide black-box risk scoring.”

Lead with:

- “We provide evidence for AI governance.”
- “We make human oversight provable.”
- “We help underwriters assess and price AI operational risk.”
- “We create claims-grade records of AI-assisted decisions.”

## Collaboration Strategy

The best collaboration request is not a broad partnership. It is a bounded pilot.

Recommended pilot ask:

> Work with Neuravant on a 30-60 day evidence pilot for AI-agent risk, focused on runtime telemetry, human oversight, control effectiveness, and underwriter-readable reporting.

Pilot outputs:

- One AI-agent risk taxonomy
- One runtime telemetry schema
- One underwriter evidence pack
- One claims attribution scenario
- One governance mapping table
- One tamper-evident evidence chain export

This keeps the conversation practical and makes it easy for an underwriter or innovation lead to say yes.

## Recommended Product Moves

Immediate product moves:

1. Add an LMA-aligned governance mapping table to the Runtime Sensor report.
2. Add explicit risk-tier fields for AI use case, business owner, human oversight, and third-party tool exposure.
3. Add a human-override scenario showing when a person approves, blocks, or corrects an agent action.
4. Add a vendor/tool-risk scenario showing external tool calls and third-party dependency risk.
5. Create a one-page underwriter evidence pack from the existing Runtime Sensor output.
6. Build a pilot template for Hiscox or Lloyd’s market participants.

These are already aligned with the current Runtime Sensor MVP and should not require a full platform rebuild.

## Bottom Line

The LMA material validates Neuravant’s direction. The Lloyd’s market is preparing for AI adoption, but adoption will be constrained by governance, evidence, explainability, oversight, and accountability requirements.

Neuravant’s strongest wedge is not “better AI.” It is **provable AI control**.

That means the core product should be framed as:

> Runtime assurance, evidence-chain integrity, and underwriter-ready governance reporting for AI-enabled insurance operations.

## Source References

- Lloyd’s Market Association, **“AI Governance in the Lloyd’s Market”**, 16 April 2026. Source page notes the LMA Survey on AI Risk Management, 39 responses, over 60% market stamp capacity, 11 interviews, 93% of respondents with an AI governance framework in place or development, and publication of the AI Adoption Toolkit.
- Lloyd’s Market Association / Barnett Waddingham, **LMA Survey on AI Risk Management**, April 2026.
- Lloyd’s Market Association, **“Artificial intelligence and machine learning in actuarial and risk”**, May 2025.
- Lloyd’s Market Association, **AI Adoption Toolkit**, referenced from the LMA AI Governance page.